RU2019104946A - Применение производного хромона в качестве антагониста дофаминового рецептора d3 для лечения расстройства аутистического спектра - Google Patents

Применение производного хромона в качестве антагониста дофаминового рецептора d3 для лечения расстройства аутистического спектра Download PDF

Info

Publication number
RU2019104946A
RU2019104946A RU2019104946A RU2019104946A RU2019104946A RU 2019104946 A RU2019104946 A RU 2019104946A RU 2019104946 A RU2019104946 A RU 2019104946A RU 2019104946 A RU2019104946 A RU 2019104946A RU 2019104946 A RU2019104946 A RU 2019104946A
Authority
RU
Russia
Prior art keywords
treatment
dophamine
chromon
antagonist
disorders
Prior art date
Application number
RU2019104946A
Other languages
English (en)
Russian (ru)
Inventor
Аньес ОКЛЕР
Пол МОЗЕР
Пьер СОКОЛОФФ
Original Assignee
Пьер Фабр Медикамент
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Пьер Фабр Медикамент filed Critical Пьер Фабр Медикамент
Publication of RU2019104946A publication Critical patent/RU2019104946A/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4168—1,3-Diazoles having a nitrogen attached in position 2, e.g. clonidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/095—Oxytocins; Vasopressins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
RU2019104946A 2013-12-13 2014-12-12 Применение производного хромона в качестве антагониста дофаминового рецептора d3 для лечения расстройства аутистического спектра RU2019104946A (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13306726.4 2013-12-13
EP13306726 2013-12-13

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
RU2016125829A Division RU2686110C1 (ru) 2013-12-13 2014-12-12 Производное хромона в качестве антагониста дофаминового рецептора d3 для применения при лечении расстройства аутистического спектра

Publications (1)

Publication Number Publication Date
RU2019104946A true RU2019104946A (ru) 2019-04-01

Family

ID=49883003

Family Applications (2)

Application Number Title Priority Date Filing Date
RU2019104946A RU2019104946A (ru) 2013-12-13 2014-12-12 Применение производного хромона в качестве антагониста дофаминового рецептора d3 для лечения расстройства аутистического спектра
RU2016125829A RU2686110C1 (ru) 2013-12-13 2014-12-12 Производное хромона в качестве антагониста дофаминового рецептора d3 для применения при лечении расстройства аутистического спектра

Family Applications After (1)

Application Number Title Priority Date Filing Date
RU2016125829A RU2686110C1 (ru) 2013-12-13 2014-12-12 Производное хромона в качестве антагониста дофаминового рецептора d3 для применения при лечении расстройства аутистического спектра

Country Status (29)

Country Link
US (1) US10028948B2 (cg-RX-API-DMAC7.html)
EP (1) EP3079688B1 (cg-RX-API-DMAC7.html)
JP (1) JP6419826B2 (cg-RX-API-DMAC7.html)
KR (1) KR102280530B1 (cg-RX-API-DMAC7.html)
CN (1) CN105792824B (cg-RX-API-DMAC7.html)
AU (1) AU2014363428B2 (cg-RX-API-DMAC7.html)
BR (1) BR112016012552A8 (cg-RX-API-DMAC7.html)
CA (1) CA2932791C (cg-RX-API-DMAC7.html)
CY (1) CY1119907T1 (cg-RX-API-DMAC7.html)
DK (1) DK3079688T3 (cg-RX-API-DMAC7.html)
ES (1) ES2657706T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20180323T8 (cg-RX-API-DMAC7.html)
HU (1) HUE036035T2 (cg-RX-API-DMAC7.html)
IL (1) IL245996B (cg-RX-API-DMAC7.html)
LT (1) LT3079688T (cg-RX-API-DMAC7.html)
MA (1) MA39076A1 (cg-RX-API-DMAC7.html)
MX (1) MX372922B (cg-RX-API-DMAC7.html)
MY (1) MY172937A (cg-RX-API-DMAC7.html)
NO (1) NO3079688T3 (cg-RX-API-DMAC7.html)
NZ (1) NZ720868A (cg-RX-API-DMAC7.html)
PL (1) PL3079688T3 (cg-RX-API-DMAC7.html)
PT (1) PT3079688T (cg-RX-API-DMAC7.html)
RS (1) RS56931B1 (cg-RX-API-DMAC7.html)
RU (2) RU2019104946A (cg-RX-API-DMAC7.html)
SA (1) SA516371298B1 (cg-RX-API-DMAC7.html)
SI (1) SI3079688T1 (cg-RX-API-DMAC7.html)
TN (1) TN2016000213A1 (cg-RX-API-DMAC7.html)
UA (1) UA117271C2 (cg-RX-API-DMAC7.html)
WO (1) WO2015086836A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2009270823B2 (en) 2008-07-16 2014-07-17 Richter Gedeon Nyrt. Pharmaceutical formulations containing dopamine receptor ligands
US11274087B2 (en) 2016-07-08 2022-03-15 Richter Gedeon Nyrt. Industrial process for the preparation of cariprazine
HU231500B1 (hu) 2019-04-10 2024-04-28 Richter Gedeon Nyrt Karbamoil-ciklohexán származékok autizmus spektrum betegség kezelésére
US11547707B2 (en) 2019-04-10 2023-01-10 Richter Gedeon Nyrt. Carbamoyl cyclohexane derivatives for treating autism spectrum disorder
CA3152645A1 (en) * 2019-09-11 2021-03-18 Oxford BioDynamics PLC Diagnostic chromosome marker
KR20220021157A (ko) 2020-08-13 2022-02-22 원광대학교산학협력단 옥시토신 호르몬 증가효과를 갖는 자폐스펙트럼장애 아동 개선용 교육시스템

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2682953B1 (fr) * 1991-10-23 1995-04-21 Inst Nat Sante Rech Med Nouveaux derives de naphtamides, leur procede de preparation et leur application dans le domaine therapeutique.
DE4229880A1 (de) * 1992-09-04 1994-03-31 Knauf Siegfried Medikament bzw. Medikamentenzusammensetzung
CA2346689A1 (en) 1998-10-08 2000-04-20 Gregor James Macdonald Tetrahydrobenzazepine derivatives useful as modulators of dopamine d3 receptors (antipsychotic agents)
WO2006034187A2 (en) * 2004-09-20 2006-03-30 Mount Sinai School Of Medicine Use of memantine (namenda) to treat autism, compulsivity, and impulsivity
EP2263665A1 (en) * 2009-06-02 2010-12-22 Pharnext New compositions for treating CMT and related disorders
FR2949465B1 (fr) * 2009-09-01 2011-08-12 Pf Medicament Derives chromones, leur procede de preparation et leurs applications therapeutiques
WO2011150380A1 (en) * 2010-05-28 2011-12-01 Xenoport, Inc. Methods of treatment of fragile x syndrome, down's syndrome, autism and related disorders
WO2012157463A1 (en) * 2011-05-13 2012-11-22 Semiconductor Energy Laboratory Co., Ltd. Semiconductor device
FR2976179A1 (fr) * 2011-06-09 2012-12-14 Pf Medicament Utilisation de la carpipramine dans le traitement de troubles psychiatriques et du developpement chez l'enfant et l'adolescent

Also Published As

Publication number Publication date
ES2657706T3 (es) 2018-03-06
MA39076A1 (fr) 2017-05-31
AU2014363428A1 (en) 2016-06-23
JP6419826B2 (ja) 2018-11-07
BR112016012552A8 (pt) 2022-11-08
KR102280530B1 (ko) 2021-07-21
EP3079688A1 (en) 2016-10-19
HK1223563A1 (zh) 2017-08-04
PL3079688T3 (pl) 2018-05-30
WO2015086836A1 (en) 2015-06-18
US10028948B2 (en) 2018-07-24
MX372922B (es) 2020-04-27
TN2016000213A1 (en) 2017-10-06
JP2016540000A (ja) 2016-12-22
IL245996A0 (en) 2016-07-31
RU2686110C1 (ru) 2019-04-24
HUE036035T2 (hu) 2018-06-28
RS56931B1 (sr) 2018-05-31
CN105792824B (zh) 2018-08-03
US20160303117A1 (en) 2016-10-20
IL245996B (en) 2018-11-29
LT3079688T (lt) 2018-02-12
SA516371298B1 (ar) 2018-06-07
NO3079688T3 (cg-RX-API-DMAC7.html) 2018-04-21
CN105792824A (zh) 2016-07-20
MX2016007612A (es) 2016-09-09
AU2014363428B2 (en) 2019-09-12
CA2932791C (en) 2021-11-09
HRP20180323T1 (hr) 2018-04-06
NZ720868A (en) 2022-04-29
CA2932791A1 (en) 2015-06-18
DK3079688T3 (da) 2018-01-29
SI3079688T1 (en) 2018-03-30
CY1119907T1 (el) 2018-06-27
PT3079688T (pt) 2018-02-28
UA117271C2 (uk) 2018-07-10
KR20160088886A (ko) 2016-07-26
MY172937A (en) 2019-12-16
HRP20180323T8 (hr) 2019-01-25
EP3079688B1 (en) 2017-11-22

Similar Documents

Publication Publication Date Title
ES2659758T3 (es) Antagonistas de receptores de 5-HT3
CY1120832T1 (el) Τροποποιητες πυρηνικης μεταφορας και χρησεις αυτων
EA201591363A1 (ru) Аналоги тиадиазола и способы лечения состояний, связанных с дефицитом smn
PH12015502628A1 (en) Pyrazolopyrrolidine derivatives and their use in the treatment of disease
PH12014502363A1 (en) N-aryltriazole compounds as lpar antagonists
PH12014502789A1 (en) N-alkyltriazole compounds as lpar antagonists
MA37400A1 (fr) Composés hétérocyclyle en tant qu'inhibiteurs de mek
MX2015016344A (es) Derivados de imidazo-pirrolidinona y su uso en el tratamiento de enfermedades.
DK2970216T3 (da) Biarylamidforbindelser som kinaseinhibitorer
UY35675A (es) Derivados sustituidos de quinazolin-4-ona
CY1118839T1 (el) Επικαλυμμενη φαρμακευτικη συνθεση που περιεχει ρεγοραφενιμπη
WO2013166037A9 (en) Non-retinoid antagonists for treatment of eye disorders
WO2015085909A8 (zh) 一种具有腺苷受体拮抗活性的氨基嘧啶杂环化合物
EA201370149A1 (ru) Антагонисты рецептора
UY34775A (es) Uso de laquinimod en alta dosis para el tratamiento de la esclerosis múltiple
WO2014153495A9 (en) Novel stat3 inhibitors
EA201692298A1 (ru) Производные карбоксамидов
HRP20180323T1 (hr) Derivat kromona kao antagonist dopaminskog receptora d3 za njegovu upotrebu u liječenju spektra autističnih poremećaja
EA201691252A1 (ru) Соединения индазола в качестве агонистов 5-ht-рецептора
EA201892529A1 (ru) Комбинация чистых антагонистов 5-htрецепторов с ингибиторами ацетилхолинэстеразы
EA201892528A1 (ru) Трехкомпонентная комбинация чистых антагонистов 5-htрецепторов, ингибиторов ацетилхолинэстеразы и антагониста nmda рецептора
WO2015059638A3 (en) Cns stimulant and opioid receptor antagonist combination as a non- addictive, non-aversive and synergistic anti-obesity treatment
EA201201530A1 (ru) Комбинация 4-{3-[цис-гексагидроциклопента[c]пиррол-2-(1h)-ил]пропокси} бензамида и антагониста nmda-рецептора и фармацевтические композиции, которые её содержат
CY1118645T1 (el) Χρηση pidotimod στη θεραπεια της ψωριασης
EA201692013A1 (ru) Новое применение n,n-бис-2-меркаптоэтил-изофталамида